Tissue engineering – a fast-growing field for advancement of medicine

21 December 2017
2019_biotech_test_vial_discovery_big

Tissue engineering, broadly described as the combination of cells, engineering methods and biochemical factors to create living biological tissue, is a fast-growing field that has the potential to significantly accelerate the advancement of medicine.

In IDTechEx’s new report, Tissue Engineering 2018 – 2028: Technologies, Markets, Forecasts, the market for engineered living tissues is forecasted to reach $4.8 billion by the year 2028.

The most obvious application of tissue engineering is in regenerative medicine, a branch of medicine that seeks to repair or replace damaged or diseased cells and tissues. Since the late 1990s, engineered skin grafts have been used to help accelerate the healing process for patients with advanced wounds such as diabetic foot and venous leg ulcers, and serious burns. Similarly, engineered cartilage grafts have been used for over a decade to repair defects in patients’ knees. We can imagine that in the far future, patients will be able to receive engineered organs, rather than wait for a matching organ to become available for transplant.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology